GlassScriptPhysician profile
Robert Y Maggin
NPI 1255322574
$1,673.96
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $338 · 2021: $720.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $298.97 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.24 | 2019-2021 | |
| Pfizer INC. | $166.25 | 2019-2021 | |
| Novo Nordisk INC | $149.61 | 2020-2021 | |
| Abbvie INC. | $143.82 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.24 | 2019-2021 | |
| Glaxosmithkline, LLC. | $107.23 | 2019-2021 | |
| Amarin Pharma, INC. | $97.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $75.17 | 2019-2021 | |
| Sanofi Pasteur INC. | $68.76 | 2019-2021 | |
| Horizon Therapeutics Plc | $50.87 | 2019-2021 | |
| Amgen INC. | $45.88 | 2019 | |
| Daiichi Sankyo INC. | $43.27 | 2021 | |
| Allergan, INC. | $40.74 | 2020 | |
| Lilly USA, LLC | $33.90 | 2019-2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.55 | 2021 | |
| Astellas Pharma US INC | $18.60 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.48 | 2020 | |
| Hologic Sales and Service, LLC | $12.13 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Maggin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.